Form 4: NAMS Chief Accounting Officer Exercises Stock Options

NewAmsterdam Pharma's Chief Accounting Officer, Louise Frederika Kooij, exercised options to acquire 18,073 ordinary shares.

Summary

• Louise Frederika Kooij, Chief Accounting Officer of NewAmsterdam Pharma Co N.V. (NAMS), exercised options to acquire 18,073 ordinary shares.
• The transaction occurred on September 2, 2025, with an exercise price of EUR 1.16392 per share.
• Following this transaction, Ms. Kooij directly holds 33,073 ordinary shares.
• The exercised options were granted on November 22, 2022, replacing an earlier option from July 6, 2021, due to the company's business combination with Frazier Lifesciences Acquisition Corporation.
• The options had a vesting schedule where 60,879 shares vested immediately on the grant date, 25% of the remaining shares vested on January 1, 2021, and the remainder vest in equal monthly installments over three years, subject to continued service.

Sentiment

Score: 6

Explanation: The exercise of options by a Chief Accounting Officer is generally a neutral to slightly positive signal, indicating confidence in the company's value, but it's a routine compensation event rather than a strategic announcement.

Positives

• An insider, the Chief Accounting Officer, increased her direct ownership in the company by exercising options, which can be interpreted as a sign of confidence in the company's future prospects.

Future Outlook

This filing reports a past insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction report, reflecting an individual executive's equity compensation activity rather than broader industry trends or competitive positioning.

Related Party Transactions

• Securities were previously held indirectly by LouFre Management B.V. for the benefit of the Reporting Person, Louise Frederika Kooij, who had the sole pecuniary interest in the securities.

Stakeholder Impact

• Shareholders may view the insider's increased direct ownership as a positive signal of management's belief in the company's value, though the impact from this single transaction is minor.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where the Chief Accounting Officer exercised stock options. While it indicates an insider's confidence in the company by increasing direct ownership, it does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason to buy or sell.

Keywords

NewAmsterdam Pharma, NAMS, SEC Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Chief Accounting Officer, Equity Compensation